Evaluate safety and efficacy of anti-PD-1/PD-L1 antibody plus chemotherapy versus anti-PD-1/PD-L1 antibody plus chemotherapy combined with bronchoscopic microwave intervention in the first-line treatment of patients with advanced central non-small cell lung cancer: a randomized prospective phase II clinical trial

Evaluate safety and efficacy of anti-PD-1/PD-L1 antibody plus chemotherapy versus anti-PD-1/PD-L1 antibody plus chemotherapy combined with bronchoscopic microwave intervention in the first-line treatment of patients with advanced central non-small cell lung cancer: a randomized prospective phase II clinical trial.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000032310

Enrollment

Unknown

Registered

2020-04-25

Start date

2020-07-01

Completion date

Unknown

Last updated

2020-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

experimental group:Anti-PD-1/PD-L1 monoclonal antibody plus chemotherapy combined with bronchoscopic microwave intervention

control group:Anti-PD-1/PD-L1 monoclonal antibody plus chemotherapy

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) All patients included in the analysis are found to have cancer cells by fiberoptic bronchoscopy or percutaneous lung biopsy, and they are confirmed as non-small cell lung cancer by immunohistochemistry. (2) Patients with obstructive central lung cancer cannot be surgically removed. (3) All patients have complete clinical and laboratory diagnostic data. (4) 18-75 (inclusive) years old, male or female. (5) Have the ability to endure bronchoscopic interventional therapy. (6) All patients agree and sign the consent form before participating in the project.

Exclusion criteria

Exclusion criteria: (1) Patients who were contraindicated by bronchoscopy. (2) Patients with tubular tumors or enlarged lymph nodes that compress airway stenosis.

Design outcomes

Secondary

Measure	Time frame
overall survival;disease control rate;adverse reaction;lung function;	—

Primary

Measure	Time frame
progression free survival;objective response rate;	—

Countries

China

Contacts

Public ContactYayi He

Shanghai Pulmonary Hospital

doctorjael@foxmail.com+86 13818828623

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026